Dr. Welch has been studying overdiagnosis for a couple of decades and has written two books, Should I Be Tested For Cancer?: Maybe Not and Here’s Why and Overdiagnosed: Making ... for. It has been pretty well established for breast cancer screening and
Researchers conducted a survey by mail among 1,600 Medicare beneficiaries 66 years or who had undergone surgery for prostate cancer or elective coronary artery stenting in 2008. ... The goal was to compare discussions about prostate cancer and stents,
New warnings on gonadotropin-releasing hormone (GnRH) agonists about the potential risk of heart disease and diabetes in men treated with these medications for prostate cancer.
An Annals of Internal Medicine editorial in the May 5 issue again notes that, “Within 10 years of trial entry, screening increases the number of cancer cases diagnosed but has no ... by overzealous therapies and like to pronounce themselves as
For example, prostate cancer screening has been in the news lately. ... More evidence suggests that screening for prostate cancer may not only be unnecessary but also potentially harmful.
Start with basic internal medicine. If an older patient with metastatic hormone-refractory prostate cancer has heart failure and shortness of breath, the best palliative care may be to treat his ... For instance, the patient may have a pulmonary embolism
You likely know several examples of “dueling guidelines,” breast cancer screening, prostate cancer screening, and goals of diabetes control.
Many clinical questions yield “competing guidelines.” We all know the controversies over breast cancer screening and prostate cancer screening.
A few months back, The New York Times reported on two new drugs, approved by the FDA for cancer treatment. ... Provenge, a new drug for prostate cancer extends life by four months at a cost of $93,000.
The furor over the lack of benefit for men of the screening Prostate Specific Antigen test (PSA) is still being heard. ... This is bad news because every year over 21,000 women are diagnosed with ovarian cancer.